Mylan NV (NASDAQ: MYL), a global pharmaceutical company, is collaborating with United States-based Gilead Sciences to expand access to the investigational antiviral remdesivir, intended for the treatment of COVID-19, it was reported on Tuesday.

The contract grants Mylan the rights to produce and distribute remdesivir in 127 low- and middle-income countries, including India. It is non-exclusive, enabling multiple licensees to ensure extensive access to this treatment, once approved as safe and effective for COVID-19 patients.

Mylan believes that it will be able to produce a bioequivalent version of remdesivir, including production of its own active pharmaceutical ingredient and the finished dosage form in sterile powder lyophilised vials for administration of the medicine by intravenous infusion.